Legal & General Group Plc Increases Position in Teva Pharmaceutical Industries Ltd. $TEVA

Legal & General Group Plc lifted its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 6.8% during the fourth quarter, Holdings Channel reports. The fund owned 3,608,387 shares of the company’s stock after purchasing an additional 228,189 shares during the quarter. Legal & General Group Plc’s holdings in Teva Pharmaceutical Industries were worth $112,618,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Allworth Financial LP increased its holdings in Teva Pharmaceutical Industries by 53.8% in the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after buying an additional 329 shares during the last quarter. Grove Bank & Trust increased its holdings in Teva Pharmaceutical Industries by 300.0% in the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after buying an additional 750 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in Teva Pharmaceutical Industries by 51.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after buying an additional 345 shares during the last quarter. Global Retirement Partners LLC increased its holdings in Teva Pharmaceutical Industries by 27.3% in the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after buying an additional 292 shares during the last quarter. Finally, 1620 Investment Advisors Inc. increased its holdings in Teva Pharmaceutical Industries by 1,823.2% in the fourth quarter. 1620 Investment Advisors Inc. now owns 1,577 shares of the company’s stock valued at $49,000 after buying an additional 1,495 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Stock Down 0.0%

NYSE:TEVA opened at $34.54 on Friday. The firm has a market capitalization of $39.72 billion, a PE ratio of 25.97, a price-to-earnings-growth ratio of 3.34 and a beta of 0.86. The stock has a 50 day moving average of $32.24 and a 200-day moving average of $31.30. Teva Pharmaceutical Industries Ltd. has a 52 week low of $14.99 and a 52 week high of $37.35. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. The company had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. Analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.49 EPS for the current year.

Analyst Ratings Changes

TEVA has been the subject of several research analyst reports. Truist Financial boosted their price objective on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, April 30th. JPMorgan Chase & Co. boosted their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Bank of America boosted their price objective on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, April 9th. UBS Group boosted their price objective on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Finally, Scotiabank boosted their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a report on Thursday, January 29th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $41.78.

Insider Activity at Teva Pharmaceutical Industries

In other news, EVP Richard Daniell sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total transaction of $1,062,000.00. Following the completion of the transaction, the executive vice president directly owned 55,755 shares of the company’s stock, valued at approximately $1,973,727. This represents a 34.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mark Sabag sold 144,180 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $34.99, for a total value of $5,044,858.20. Following the transaction, the insider directly owned 80,760 shares of the company’s stock, valued at $2,825,792.40. This trade represents a 64.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 934,459 shares of company stock valued at $31,122,931. 0.54% of the stock is owned by insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.